Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Clinical Trial to Evaluate the Effects of a Plant-Based Liquid Supplement on Metabolic Health and Overall Well-Being

23. juni 2026 opdateret af: Biocol Labs
This single-arm clinical trial will evaluate the effects of a plant-based liquid supplement on metabolic health, digestive health, skin health, and overall well-being. Twenty participants aged 40 to 60 years with elevated alanine transaminase (ALT) or aspartate transaminase (AST) levels will use the supplement daily for 90 days. Participants will complete questionnaires, provide body composition and waist circumference measurements, submit photographs, and undergo blood testing throughout the study. Outcomes include changes in metabolic biomarkers, body composition, digestive symptoms, skin health, and overall well-being.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

20

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Nevada
      • Las Vegas, Nevada, Forenede Stater, 89118
        • Citruslabs

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  • Age 40 to 60 years
  • Elevated ALT or AST identified during prescreening blood testing
  • Currently experiencing at least two of the following:

Stomach discomfort, Constipation, Diarrhea, Heartburn, Bloating, Gas, Abdominal pain, Skin redness or pimples, Sugar cravings

  • Willing to comply with study requirements
  • Willing to discontinue supplements or herbal remedies targeting detoxification, digestive health, liver function, or skin health during the study
  • Willing to avoid starting new products, medications, or supplements targeting detoxification, digestive health, liver function, or skin health
  • Willing to maintain normal diet, sleep patterns, and activity levels
  • Generally healthy without uncontrolled chronic disease
  • Resides in the United States
  • Not participating in another research study during the study period
  • Has access to a study partner to take study photographs

Exclusion Criteria:

  • Severe digestive disorders including acid reflux, IBS, IBD, Crohn's disease, or gastrointestinal tract surgeries
  • Liver disease
  • Known allergy or hypersensitivity to study product ingredients Chronic conditions that would interfere with study participation, including oncological or psychiatric disorders
  • Known severe allergic reactions
  • Pregnant, breastfeeding, or attempting to conceive
  • Unwilling to follow study procedures
  • Stopped hormonal birth control within the past month
  • History of substance abuse
  • Use of prescription diabetes medications, including GLP-1 receptor agonists such as Ozempic, Wegovy, or Mounjaro

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Plant-Based Liquid Supplement
Participants will consume one ampule of the study product diluted in approximately 8 ounces of water before the first meal of the day throughout the study period.
A liquid dietary supplement containing choline bitartrate, zinc sulfate, manganese sulfate, artichoke leaf extract, fennel extract, rosemary leaf extract, L-arginine monohydrochloride, inositol, bromelain, papain, sorbitol, glycerin, artificial flavour, and potassium sorbate.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in Body Weight
Tidsramme: Baseline, Day 30, Day 60, and Day 90.
Change in body weight measured using a Withings smart scale.
Baseline, Day 30, Day 60, and Day 90.
Change in Waist Circumference
Tidsramme: Baseline, Day 7, Day 30, Day 60, and Day 90.
Change in waist circumference measured using a tape measure and recorded in centimeters.
Baseline, Day 7, Day 30, Day 60, and Day 90.
Change in Body Fat Mass
Tidsramme: Baseline, Day 7, Day 30, Day 60, and Day 90.
Change in body fat mass measured using a Withings smart scale.
Baseline, Day 7, Day 30, Day 60, and Day 90.
Change in Lean Body Mass
Tidsramme: Baseline, Day 7, Day 30, Day 60, and Day 90.
Change in lean body mass measured using a Withings smart scale.
Baseline, Day 7, Day 30, Day 60, and Day 90.
Change in Visceral Fat Index
Tidsramme: Baseline, Day 7, Day 30, Day 60, and Day 90.
Change in visceral fat index measured using a Withings smart scale.
Baseline, Day 7, Day 30, Day 60, and Day 90.
Change in Alanine Aminotransferase (ALT)
Tidsramme: Baseline, Day 30, Day 60, and Day 90.
Change in serum alanine aminotransferase concentration measured by hepatic function panel.
Baseline, Day 30, Day 60, and Day 90.
Change in Aspartate Aminotransferase (AST)
Tidsramme: Baseline, Day 30, Day 60, and Day 90
Change in serum aspartate aminotransferase concentration measured by hepatic function panel.
Baseline, Day 30, Day 60, and Day 90
Change in Alkaline Phosphatase (ALP)
Tidsramme: Baseline, Day 30, Day 60, and Day 90.
Change in serum alkaline phosphatase concentration measured by hepatic function panel.
Baseline, Day 30, Day 60, and Day 90.
Change in Total Bilirubin
Tidsramme: Baseline, Day 30, Day 60, and Day 90.
Change in serum total bilirubin concentration measured by hepatic function panel.
Baseline, Day 30, Day 60, and Day 90.
Change in Total Cholesterol
Tidsramme: Baseline, Day 30, Day 60, and Day 90.
Change in serum total cholesterol concentration measured by lipid panel.
Baseline, Day 30, Day 60, and Day 90.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in Participant-Reported Bloating Severity
Tidsramme: Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
Change in participant-reported bloating severity assessed by study questionnaire.
Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
Change in Participant-Reported Flatulence Severity
Tidsramme: Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
Change in participant-reported flatulence severity assessed by study questionnaire.
Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
Change in Participant-Reported Heartburn Severity
Tidsramme: Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
Change in participant-reported heartburn severity assessed by study questionnaire.
Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
Change in Participant-Reported Digestive Comfort
Tidsramme: Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
Change in participant-reported digestive comfort assessed by study questionnaire.
Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
Change in Participant-Reported Skin Health
Tidsramme: Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
Change in participant-reported skin health assessed by study questionnaire.
Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

5. juni 2025

Primær færdiggørelse (Faktiske)

15. januar 2026

Studieafslutning (Faktiske)

15. januar 2026

Datoer for studieregistrering

Først indsendt

23. juni 2026

Først indsendt, der opfyldte QC-kriterier

23. juni 2026

Først opslået (Faktiske)

29. juni 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

29. juni 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

23. juni 2026

Sidst verificeret

1. juni 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • #20758

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner